Otologic Pharmaceutics, Inc. (OPI)

OPI is developing oral therapeutics that address noise-induced hearing loss.

  • Stage Product In Development
  • Industry Other
  • Location Oklahoma City, OK, USA
  • Currency USD
  • Founded January 2009
  • Employees 5
  • Website otologicpharmaceutics.com

Company Summary

Oklahoma-headquartered organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing health. The combined research and business experience of the Hough Ear Institute, Oklahoma Medical Research Foundation and American Biohealth Group, have partnered to form OPI to develop therapeutic agents to treat acute noise induced hearing loss.

Team

  • Kirk Maples PhD
    Consultant

  • Richard Gammans PhD MSM
    President and Chief Operating Officer

  • Clayton Duncan
    Chief Executive Officer

  • Rick Kopke MD
    Chief Medical Officer

  • Robert Floyd PhD
    Chief Science Officer

  • Clayton Duncan

Advisors

  • Cooley, LLP
    Lawyer
    Unconfirmed
    Cole and Reed LLP
    Accountant
    Unconfirmed

Previous Investors

  • OMRF, INTEGRIS HEALTH, i2E, OCAST
    Unconfirmed
    Founders- Karlman, Kopke, Floyd
    Unconfirmed
    Consultants discounted billing rate in exchange for stock
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free